Promoted for
Mobile Users
Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
How to buy Abiomed stock in Canada | $281.47
Own Abiomed shares in just a few minutes.
Abiomed, Inc is a medical devices business based in the US. Abiomed shares (ABMD.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $281.47 – an increase of 1.63% over the previous week. Abiomed employs 1,536 staff and has a trailing 12-month revenue of around $802.9 million.
How to buy shares in Abiomed
- Choose a platform. If you're a beginner, our share-dealing table below can help you choose.
- Open your account. You'll need your ID, bank details and national insurance number.
- Confirm your payment details. You'll need to fund your account with a bank transfer, debit card or credit card.
- Search the platform for stock code: ABMD in this case.
- Research Abiomed shares. The platform should provide the latest information available.
- Buy your Abiomed shares. It's that simple.
What's in this guide?
- Can I buy shares in Abiomed?
- Has coronavirus impacted Abiomed shares?
- Abiomed shares summary
- Compare share dealing platforms
- Is Abiomed stock a buy or sell?
- Abiomed performance over time
- Can I short Abiomed shares?
- Are Abiomed shares over-valued?
- Abiomed's financials
- How volatile are Abiomed shares?
- Does Abiomed pay a dividend?
- Have Abiomed shares ever split?
- Other common questions
How has Coronavirus impacted Abiomed's share price?
Since the stock market crash in March caused by coronavirus, Abiomed's share price has had significant positive movement.
Its last market close was $281.47, which is 40.76% up on its pre-crash value of $166.74 and 136.51% up on the lowest point reached during the March crash when the shares fell as low as $119.0101.
If you had bought $1,000 worth of Abiomed shares at the start of February 2020, those shares would have been worth $711.99 at the bottom of the March crash, and if you held on to them, then as of the last market close they'd be worth $1,514.31.
Abiomed share price
Use our graph to track the performance of ABMD stocks over time.Abiomed shares at a glance
Information last updated 2020-11-27.
| Latest market close | $281.47 |
|---|---|
| 52-week range | $119.0101 - $319.19 |
| 50-day moving average | $272.5354 |
| 200-day moving average | $267.5902 |
| Wall St. target price | $312.4 |
| PE ratio | 57.9824 |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $4.55 |
Compare online trading platforms
Is it a good time to buy Abiomed stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Abiomed price performance over time
Historical closes compared with the last close of $281.47
| 1 week (2020-11-25) | 6.69% |
|---|---|
| 1 month (2020-11-02) | 10.45% |
| 3 months (2020-09-02) | -10.00% |
| 6 months (2020-06-02) | 22.03% |
| 1 year (2019-12-02) | 46.43% |
|---|---|
| 2 years (2018-11-30) | -15.39% |
| 3 years (2017-12-01) | 44.64% |
| 5 years (2015-12-02) | 232.24% |
Is Abiomed under- or over-valued?
Valuing Abiomed stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Abiomed's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Abiomed's P/E ratio
Abiomed's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 58x. In other words, Abiomed shares trade at around 58x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Abiomed's PEG ratio
Abiomed's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.75. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Abiomed's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
Abiomed's EBITDA
Abiomed's EBITDA (earnings before interest, taxes, depreciation and amortisation) is USD$248 million.
The EBITDA is a measure of a Abiomed's overall financial performance and is widely used to measure a its profitability.
Abiomed financials
| Revenue TTM | USD$802.9 million |
|---|---|
| Operating margin TTM | 28.09% |
| Gross profit TTM | USD$689.6 million |
| Return on assets TTM | 11.49% |
| Return on equity TTM | 19.12% |
| Profit margin | 25.88% |
| Book value | $26.165 |
| Market capitalisation | USD$11.9 billion |
TTM: trailing 12 months
How to short and sell Abiomed shares
- Create a CFD or spread betting account.
- Search for the stock code. E.g. "ABMD.US"
- Choose your position size.
- Select "sell" rather than "buy".
- Confirm your position and keep tabs on it. You may wish to set limits on your position.
There are currently 2.3 million Abiomed shares held short by investors – that's known as Abiomed's "short interest". This figure is 6.9% down from 2.4 million last month.
There are a few different ways that this level of interest in shorting Abiomed shares can be evaluated.
Abiomed's "short interest ratio" (SIR)
Abiomed's "short interest ratio" (SIR) is the quantity of Abiomed shares currently shorted divided by the average quantity of Abiomed shares traded daily (recently around 334031.12094395). Abiomed's SIR currently stands at 6.78. In other words for every 100,000 Abiomed shares traded daily on the market, roughly 6780 shares are currently held short.
However Abiomed's short interest can also be evaluated against the total number of Abiomed shares, or, against the total number of tradable Abiomed shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Abiomed's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Abiomed shares in existence, roughly 50 shares are currently held short) or 0.052% of the tradable shares (for every 100,000 tradable Abiomed shares, roughly 52 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Abiomed.
Find out more about how you can short Abiomed stock.
Abiomed share dividends
We're not expecting Abiomed to pay a dividend over the next 12 months. However, you can browse other dividend-paying shares in our guide.
Have Abiomed's shares ever split?
Abiomed's shares were split on a 2:1 basis on 2 October 2000. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Abiomed shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Abiomed shares which in turn could have impacted Abiomed's share price.
Abiomed share price volatility
Over the last 12 months, Abiomed's shares have ranged in value from as little as $119.0101 up to $319.19. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Abiomed's is 1.4256. This would suggest that Abiomed's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).
Abiomed overview
Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella CP, a device used by interventional cardiologists to support patients in the cath lab and cardiac surgeons in the heart surgery suite. It also provides Impella 5.0 and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; and Impella Connect, a cloud-based technology that enables secure, cloud-based, and remote viewing of the Automated Impella Controller for physicians and hospital staffs. In addition, the company engages in the development of Impella XR Sheath, a sheath designed to expand and recoil to all for ease of use upon insertion of an Impella heart pump and minimize the size of the arteriotomy; Impella BTR, a percutaneous micro heart pumps with integrated motors and sensors; and Impella ECP pump that is designed for blood flow of greater than three liters per minute. It sells its products through direct sales and clinical support personnel in the United States, Canada, Europe, and Asia. The company was founded in 1981 and is headquartered in Danvers, Massachusetts.
Frequently asked questions
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.
More guides on Finder
-
How to buy Conagra Brands stock in Canada | $37.47
Steps to owning and managing Conagra Brands stocks, with 24-hour and historical pricing before you buy.
-
How to buy Xilinx stock in Canada | $118.02
Steps to owning and managing Xilinx stocks, with 24-hour and historical pricing before you buy.
-
How to buy Lufax Holding stock in Canada
Steps to owning and managing Lufax Holding stocks, with 24-hour and historical pricing before you buy.
-
How to buy Covetrus stock in Canada | $27.24
Steps to owning and managing Covetrus stocks, with 24-hour and historical pricing before you buy.
-
How to buy Codiak BioSciences stock in Canada
Steps to owning and managing Codiak BioSciences stocks, with 24-hour and historical pricing before you buy.
-
How to buy Celanese Corporation stock in Canada | $117.7
Steps to owning and managing Celanese Corporation stocks, with 24-hour and historical pricing before you buy.
-
How to buy Praxis Precision Medicines stock in Canada
Steps to owning and managing Praxis Precision Medicines stocks, with 24-hour and historical pricing before you buy.
-
How to buy Kronos Bio stock in Canada
Steps to owning and managing Kronos Bio stocks, with 24-hour and historical pricing before you buy.
-
How to buy GoodRx stock in Canada | $50.14
Steps to owning and managing GoodRx stocks, with 24-hour and historical pricing before you buy.